Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
Year: 2014
Type: article
Abstract: Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML). This updated analysis of the BELA trial assessed the safety profile and management of toxicities of bosutinib versus imatinib in adults with newly diagnosed (≤6 months) CP CML after >30 months from accrual completion. Among patients randomized to bosutinib 500 mg/d (n = 250) or imatinib 400 mg/d (n = 252), 248 and 251, respectively, received ≥1 dose of study treatment. Adverse events (AEs; any grade) with bosutinib versus imatinib were significantly more common for certain gastrointestinal events (diarrhea, 70% vs. 26%; P < 0.001; vomiting, 33% vs. 16%; P < 0.001), alanine aminotransferase (33% vs. 9%; P < 0.001) and aspartate aminotransferase (28% vs. 10%; P < 0.001) elevations, and pyrexia (19% vs. 12%; P = 0.046). AEs significantly less common with bosutinib included edema (periorbital, 2% vs. 14%; P < 0.001; peripheral, 5% vs. 12%; P = 0.006), musculoskeletal (myalgia, 5% vs. 12%; P = 0.010; muscle cramps, 5% vs. 22%; P < 0.001; bone pain, 4% vs. 11%; P = 0.003), increased creatine phosphokinase (8% vs. 20%; P < 0.001), neutropenia (13% vs. 30%; P < 0.001), and leukopenia (9% vs. 22%; P < 0.001). Between-group differences in the incidence of cardiac and vascular AEs were not significant. Diarrhea was typically transient, mostly Grade 1/2, occurring early during treatment, and was manageable with antidiarrheal medication. Despite higher rates of aminotransferase elevation with bosutinib, events were managed in most patients with dose modification and/or concomitant medication. Bosutinib had a manageable safety profile distinct from that of imatinib in patients with newly diagnosed CP CML.
Source: American Journal of Hematology
DOI: 10.1002/ajh.23788
Institutions: University of Milano-Bicocca, The University of Texas MD Anderson Cancer Center, Princess Margaret Cancer Centre, Medical University of Lublin, Chinese University of Hong Kong, Prince of Wales Hospital, Samara Regional Clinical Hospital named after V.D. Seredavina, Pfizer (United States), Pfizer (France), Tata Memorial Hospital, University Medical Center Hamburg-Eppendorf, Universitätsklinikum Aachen, RWTH Aachen University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: bosutinib, imatinib, chronic phase CML, newly diagnosed CML, drug safety, adverse events, diarrhea, gastrointestinal toxicity, hepatotoxicity, neutropenia, leukopenia, adverse cardiac events, vascular adverse events, tyrosine kinase inhibitors, long-term follow-up, treatment discontinuation
Open Access status: hybrid
Estimated APC paid: $5,450
Award: Cancer Center Support Grant
OpenAlex ID: W1490900965
